CASRAI Dictionary

Tag: research misconduct investigation

  • Elsevier’s Research Integrity Screening Process

    Elsevier screens research submissions for integrity issues through a layered pipeline: automated tools such as Check Integrity and Crossref Similarity Check flag plagiarism, duplicate submissions and image anomalies at intake, specialist Research Integrity and Publishing Ethics (RIPE) analysts investigate confirmed concerns, and outcomes range from correction through expression of concern to full retraction, following guidelines set by the Committee on Publication Ethics (COPE).

    Research integrity screening is the set of technical checks and human review stages a publisher applies to a manuscript, before and after publication, to detect fabrication, falsification, plagiarism, undisclosed image manipulation and paper-mill activity. At Elsevier, that pipeline runs continuously from the moment a manuscript is submitted to the point, if necessary, of retraction.

    How Elsevier’s research-integrity pipeline works, from submission to retraction

    Elsevier operates one of the largest editorial screening operations in scholarly publishing. In 2025, the publisher received 4.2 million manuscript submissions across roughly 3,000 journals and published 795,000 after validation and peer review, according to Elsevier’s own account of its editorial process. Elsevier states that its published output accounts for over 18% of global research output and 29% of citations — a scale that shapes why it has invested heavily in both automated screening and dedicated integrity staff rather than relying on peer review alone.

    The pipeline runs across four broad stages, each with a different primary tool or team responsible for catching a different class of problem.

    Stage Primary tool or team Typical trigger
    Submission intake Check Integrity screening tool; Crossref Similarity Check (iThenticate) Text overlap, duplicate manuscript, unauthorised authorship change
    Peer review Editors, external reviewers, RIPE analysts Implausible data, reviewer-flagged inconsistency, suspicious image reuse
    Post-publication monitoring Research Integrity and Publishing Ethics (RIPE) team Reader or whistleblower reports, cross-journal pattern analysis
    Enforcement Editors-in-chief, following COPE-guided process Confirmed fabrication, falsification or plagiarism

    What does Elsevier screen for at the point of submission?

    Every manuscript submitted to an Elsevier journal is routed through automated checks before an editor sees it. Check Integrity, Elsevier’s proprietary screening tool, had been expanded across more than 2,000 journals as of March 2026, according to trade press coverage in Research Information. The tool automatically reviews submissions for red flags — including unauthorised authorship changes, undisclosed conflicts of interest and signs of duplicate or template-like submission — and routes anything flagged to specialist integrity analysts, freeing editors to focus on scientific merit.

    Plagiarism screening runs in parallel through Crossref Similarity Check, powered by iThenticate, which compares submitted text against a large index of published articles and web content. There is no fixed similarity percentage that automatically triggers rejection; editors interpret each report to distinguish appropriate citation from genuine textual misconduct.

    Paper-mill detection layers on top of these checks. Integrity analysts look for patterns that recur across industrialised fraud, including:

    • Formulaic, template-like titles or methods sections
    • Unusual or inconsistent author affiliations and contact details
    • Data or experimental descriptions that do not match the stated methodology
    • Systematic image reuse across ostensibly unrelated papers
    • Irregular peer-review patterns, such as reviewer suggestions tied to the same small pool of contacts

    How does Elsevier detect image manipulation and data-integrity problems?

    Image screening combines editorial guidelines with a mix of manual and software-assisted checks. Elsevier’s policy permits minor adjustments to brightness, contrast or colour balance only where they do not obscure or eliminate information present in the original image; the use of generative AI to create or alter a figure is prohibited outright. Where manipulation is suspected, editors can apply forensic image-analysis tools of the kind recommended by the US Office of Research Integrity, and will typically request the original, unprocessed image files directly from the authors.

    Elsevier has also published on the scale of automated flagging behind these checks. At the 8th World Conference on Research Integrity in 2024, Elsevier data scientist Yuri Kashnitsky presented on large-scale flagging of integrity misconduct across the publisher’s portfolio, noting that all system-generated findings are manually checked and confirmed by investigators before any corrective action is suggested to editors — underscoring that software narrows the search space, but a human analyst still makes the determination.

    Who investigates confirmed misconduct, and what enforcement follows?

    Once a concern is substantiated, Elsevier’s in-house Research Integrity and Publishing Ethics (RIPE) team leads the investigation, working with journal editors and, where warranted, the authors’ institutions. Elsevier states that it follows retraction guidelines developed by COPE, and confirmed problems resolve into one of three outcomes: a correction or erratum for errors that do not undermine the paper’s conclusions, an expression of concern where the investigation is inconclusive but doubts remain, or a retraction where the findings are no longer considered reliable.

    A recent case shows this enforcement ladder operating at scale. In a statement updated in May 2026, Elsevier disclosed that a comprehensive, multi-year audit of the journal Heliyon — using Check Integrity screening combined with manual review by RIPE analysts — had produced approximately 1,100 corrections to the scientific record, affecting around 3% of everything the journal had published across 12 years. Those 1,100 actions spanned corrections, expressions of concern and retractions; impacted authors were notified and given the chance to respond before editors made a final determination. Following the audit, Web of Science removed an indexing hold it had placed on Heliyon, and Elsevier said it was applying lessons from the case to workflows across its wider journal portfolio.

    Common questions about Elsevier’s integrity screening

    Does Elsevier use iThenticate for plagiarism screening?

    Yes. Elsevier’s journals route submitted manuscripts through Crossref Similarity Check, which is powered by iThenticate, comparing text against a large index of published articles and web content. Editors, not the software alone, judge whether flagged overlap reflects proper citation or genuine plagiarism before any editorial decision is made.

    Who investigates allegations of research misconduct at Elsevier?

    Elsevier’s in-house Research Integrity and Publishing Ethics (RIPE) team investigates confirmed concerns, working alongside journal editors and, where relevant, the authors’ institutions. Investigations follow COPE guidelines and typically involve requesting raw underlying data before any corrective action is taken.

    What is considered the most serious form of research misconduct?

    Fabrication and falsification of data are generally treated as the most serious forms of misconduct, alongside plagiarism, because they directly corrupt the reliability of the published record. Elsevier’s policies place these above lesser breaches such as citation gaming or unresolved authorship disputes.

    What happens after a research-integrity investigation confirms a problem?

    Confirmed issues lead to one of three outcomes: a correction for errors that do not undermine the findings, an expression of concern where evidence is inconclusive, or a retraction where the results are no longer considered reliable. All three are published and linked to the original article, per COPE guidance.

    What this means for institutions, authors and integrity offices

    For research administrators, the Heliyon case is a reminder that publisher-side screening is a complement to institutional processes, not a substitute for them. When a journal’s RIPE team contacts an institution about a flagged submission or published paper, that request typically triggers — and depends on — the institution’s own research-integrity office and record-keeping, an area covered in more detail in CASRAI’s research administration resources and its wider research-integrity dictionary entries. Authors, in turn, should expect to be asked for raw, unprocessed data or images at any stage, including years after publication, and should retain those records accordingly.

    Elsevier is not acting alone: it collaborates with other publishers through the STM Integrity Hub to detect duplicate submissions across the wider industry, reflecting a broader shift toward cross-publisher, not just single-journal, integrity infrastructure. As automated screening tools mature, the balance is likely to keep shifting toward earlier detection at submission — but the Heliyon audit shows that human RIPE analysts, not algorithms, remain the ones who make the final call on correction, expression of concern or retraction.

  • Publication Misconduct in Research: The Post-Publication Process

    Publication misconduct in research discovered after a paper is already public triggers a defined post-publication pipeline: a reader or institution files a complaint, the journal opens a formal investigation guided by COPE, an expression of concern may be issued while it runs, and a retraction or correction follows if misconduct is confirmed.

    Publication misconduct is unethical conduct in the publishing process itself — fabrication, falsification, plagiarism, duplicate submission, or fraudulent (ghost, guest or gift) authorship — as distinct from poor research design or an honest error in the underlying study. Once a flawed paper has already been indexed, cited and built upon, the mechanics of fixing the record are entirely different from catching the same problem at peer review. This article sets out what actually happens once that process starts, who runs it, and how the outcome gets communicated to readers and indexers.

    What counts as publication misconduct once a paper is already public?

    Publication misconduct covers conduct in the writing and submission of a paper, not the underlying experiment: fabrication (inventing data), falsification (manipulating images, figures or results), plagiarism, duplicate or redundant publication, and fraudulent authorship such as ghost, guest or gift authorship. The Royal Society’s publishing ethics policy defines research misconduct as “fabrication, falsification, or plagiarism in proposing, performing, or reviewing research, or in reporting research results” — and explicitly excludes “honest error or differences of opinion” from that definition.

    That exclusion matters at the post-publication stage. An editor’s first job on receiving a complaint is not to assume guilt but to classify the report: is this a correctable mistake, an authorship dispute, or a potential integrity breach that needs a formal case? Only the third category enters the investigation pipeline described below.

    What triggers a post-publication review?

    Post-publication scrutiny rarely originates with the journal itself. It is most often triggered externally, then formalised internally once a case is opened.

    • Reader or third-party complaints — direct emails to the editor, or public flags on post-publication review platforms such as PubPeer.
    • Institutional referral — a university research integrity office notifies the journal after its own internal inquiry.
    • Journal screening tools — image-manipulation and paper-mill detection software run against submitted or already-published figures.
    • Whistleblowers — co-authors, former colleagues or lab members raising concerns directly.
    • Funder or sponsor notice — a grant body flags a discrepancy found during its own audit.

    Under the ICMJE Recommendations, editors who receive “convincing evidence” of misconduct have a duty to pursue the matter — including by contacting the authors’ institution — rather than simply declining to act on an anonymous tip.

    How does the editorial investigation actually run?

    Once a case is opened, the journal follows a sequence set out in COPE’s guidance rather than improvising case by case. The Committee on Publication Ethics (COPE) Retraction Guidelines (2019) and its accompanying flowcharts are the reference most editors use to decide what to do next, and in what order.

    1. Initial screening — the editor checks whether the complaint is plausible and falls within the journal’s remit.
    2. Author response — the corresponding author is asked to explain, and usually to supply raw data, original images or lab records.
    3. Institutional referral — if the explanation is unsatisfactory or the allegation is serious, the editor notifies the authors’ institution, which runs its own inquiry under its research integrity policy; the journal does not adjudicate misconduct itself.
    4. Interim notice — while the inquiry is unresolved, the journal may publish an editorial expression of concern attached to the paper.
    5. Final notice — depending on the outcome, the journal publishes a correction, a retraction, or lifts the expression of concern with no further action.

    This sequencing is the core distinction between research-stage and publication-stage misconduct handling: at the research stage, a funder or institution can simply stop a study; at the publication stage, the journal must communicate every step publicly, because the paper is already part of the citable literature.

    Retraction, correction, or expression of concern — what is the difference?

    These three notice types are not interchangeable, and mixing them up is one of the most common errors in coverage of publication misconduct. Each has a distinct trigger, a distinct effect on the paper’s citability, and a distinct authority that can issue it.

    Notice type When it is issued Effect on the paper Who can issue it
    Correction / erratum / corrigendum An error is confirmed but conclusions still hold Paper stands; correction is linked to it Editor, with author agreement
    Editorial expression of concern Investigation is open but unresolved Paper stands but is flagged as unreliable pending outcome Editor, independently of authors
    Retraction Misconduct or unreliable findings confirmed Paper is marked “RETRACTED” but remains accessible for transparency Editor, authors, or institution

    A retracted paper is not deleted. Standard practice, reflected in NISO RP-45-2022, Communication of Retractions, Removals, and Expressions of Concern (CREC), requires the original text to remain online with a clear, permanent watermark and a linked retraction notice explaining the reason — so the scientific record stays transparent rather than simply erased. Since 2023, Crossref has hosted the freely available Retraction Watch Database, giving publishers, institutions and reference managers a shared, machine-readable source of retraction metadata rather than relying on scattered publisher notices alone.

    Common questions about post-publication misconduct

    What is the difference between a retraction, a correction, and an expression of concern?

    A correction fixes a confirmed error while the paper’s conclusions stand. An expression of concern flags an unresolved investigation without prejudging guilt. A retraction is issued once misconduct or unreliable findings are confirmed, permanently marking the paper as withdrawn from the reliable literature while keeping it accessible.

    What triggers a post-publication misconduct investigation?

    Investigations are usually triggered by a reader complaint, a post-publication review platform flag, an institutional referral, a whistleblower report, or automated screening for image manipulation or paper-mill patterns. Under the ICMJE Recommendations, editors receiving credible evidence have a duty to pursue it rather than dismiss it.

    Does a retracted paper disappear from the internet?

    No. Under NISO’s CREC recommended practice, retracted articles must remain accessible with a permanent watermark and a linked retraction notice. Removal is reserved for rare cases involving legal risk, such as defamation or serious safety hazards, not ordinary misconduct findings.

    Who decides whether a published paper is retracted?

    The journal editor makes the final call, but the decision is informed by the authors’ institution, which runs the substantive misconduct inquiry. COPE’s Retraction Guidelines position the journal as the notice-issuing authority and the institution as the fact-finding authority — the two roles are kept deliberately separate.

    What does this mean for institutions and authors?

    For research administrators, a post-publication complaint is not a journal-only event. Institutions are expected to run a parallel inquiry, respond to editor requests for data within a defined timeframe, and — if misconduct is confirmed — cooperate on the retraction notice’s wording under COPE guidance. Authors named on a retracted paper should expect it to be discoverable through Crossref’s Retraction Watch Database and CrossMark update badges wherever it is cited or indexed, regardless of original host.

    Contributor-role clarity also matters here: disputes over who is accountable for which part of a paper are easier to resolve when contributions were recorded precisely at submission. CASRAI’s authorship resources and research administration guidance cover structuring that accountability before a dispute reaches an editor’s desk.

    Where the retraction pipeline is heading

    Two shifts are changing post-publication misconduct handling. First, machine-readable retraction metadata — now centralised at Crossref rather than scattered across publisher sites — propagates a retraction to citation databases and discovery layers automatically, closing a gap that once left retracted papers silently cited for years. Second, paper-mill detection is shifting discovery earlier, toward pre-publication screening — but the CREC-based post-publication pipeline remains the backstop for everything that gets through regardless. The mark of a well-functioning system is not the absence of retractions; it is a transparent, standardised trail from complaint to notice that any reader can follow.

  • Research Misconduct Federal Funding: Grant Risk

    When an allegation of research misconduct is opened against a federally funded project, the grant does not simply continue as normal. The funding agency can defer draw-downs, restrict how funds are spent, or suspend the award outright, while the awardee institution — not the agency — conducts the inquiry and investigation under research misconduct federal funding rules that require prompt notification, safeguarding of funds, and, if misconduct is confirmed, cost recovery or debarment.

    Research misconduct is fabrication, falsification, or plagiarism in proposing, performing, or reviewing federally funded research, or in reporting its results — a definition set by the Office of Science and Technology Policy’s 2000 Federal Policy on Research Misconduct (65 Fed. Reg. 76,260) and applied by every major federal research funder.

    What Is Research Misconduct Under Federal Policy?

    Federal research misconduct policy applies a single, government-wide standard: fabrication, falsification, or plagiarism (FFP) committed in proposing, performing, or reviewing federally funded research, or in reporting its results. Under the OSTP Federal Policy on Research Misconduct, a finding requires proof that the conduct represents “a significant departure from accepted practices,” was committed “intentionally, or knowingly, or recklessly,” and is established “by a preponderance of the evidence” — a civil, not criminal, standard.

    Honest error and legitimate differences of scientific opinion are explicitly excluded. The policy also does not cover authorship disputes, harassment, or general grant-management violations, which fall under separate institutional or agency processes.

    • Fabrication — making up data or results and recording or reporting them.
    • Falsification — manipulating materials, equipment, or data so the research record is not accurately represented.
    • Plagiarism — appropriating another person’s ideas, processes, results, or words without credit.

    What Happens to Grant Funds During an Investigation?

    A grant under a misconduct inquiry does not automatically stop, but the funding agency retains authority to take interim administrative actions to protect federal funds while the institution investigates. These typically include deferring decisions on continued funding, restricting the purposes for which existing funds may be spent, requiring special award certifications, or — where the risk is severe — suspending the active award pending outcome.

    Responsibility for the investigation sits primarily with the recipient institution, not the funder. Under Public Health Service (PHS) rules governing NIH-funded research (42 CFR Part 93), and the parallel National Science Foundation framework (45 CFR Part 689), the institution runs its own inquiry and investigation while the agency monitors, can intervene, and controls the purse strings throughout.

    Investigation stage Typical fund status Who acts
    Institutional assessment / inquiry Funds usually continue; agency may be informed Research Integrity Officer (RIO)
    Formal investigation opened Agency may defer, restrict, or condition funding Institution investigates; ORI or NSF OIG notified
    Investigation concluded, misconduct found Suspension, termination, or debarment possible Agency Inspector General / Deciding Official

    Who Must Notify the Funding Agency, and When?

    Every institution receiving PHS or NSF funding is required, as a condition of its funding assurance, to notify the relevant federal office once a formal investigation is opened. For NIH and other Public Health Service awards, that notice goes to HHS’s Office of Research Integrity (ORI); for NSF awards, it goes to the NSF Office of Inspector General (OIG).

    Notification cannot wait for the case to close. If the institution determines during an inquiry or investigation that public health or safety is at risk, that federal interests or resources are threatened, that research activities should be suspended, or that there is a reasonable indication of a possible civil or criminal law violation, it must notify the agency immediately — not at the standard reporting milestones.

    • Immediate notice — health/safety risk, threat to federal resources, or suspected civil/criminal violation.
    • Formal notice at investigation opening — required under the institution’s PHS or NSF assurance.
    • Closing report — the full institutional record, transmitted to ORI or NSF OIG after a final misconduct determination and any institutional appeal.

    What Are the Consequences If Misconduct Is Confirmed?

    If an investigation substantiates research misconduct, the funding agency can impose administrative sanctions independent of, and in addition to, any action the institution itself takes. Under ORI’s guidance on federal policy, “the Federal Government can debar researchers who commit misconduct from receiving Federal funds for a specified period of time,” and institutions commonly pursue their own parallel actions such as termination of employment or mandated supervision of future work.

    Available federal administrative actions include:

    • Correction of the published research record and retraction of affected papers.
    • Letters of reprimand or special certification requirements on future awards.
    • Suspension or termination of the active award, with recovery of misspent federal funds.
    • Suspension or debarment from federal funding, published on the General Services Administration’s SAM.gov exclusions list.
    • Referral to the Department of Justice where civil or criminal fraud is suspected.

    Cost recovery is a distinct lever from debarment: an institution can be required to repay funds tied to fabricated or falsified data even where an individual researcher, not the institution, is the primary respondent.

    How Does the 2024 Final Rule Change the Process?

    The compliance landscape shifted materially with HHS’s Final Rule updating 42 CFR Part 93, published in the Federal Register on 17 September 2024 and formally titled “Public Health Service Policies on Research Misconduct.” The rule took effect 1 January 2025, but institutions were required to apply its new procedural requirements to any allegation received on or after 1 January 2026, with updated institutional policies due to ORI no later than the annual report covering 2025 (filed by 30 April 2026).

    The Final Rule extends two of the timelines research administrators rely on most:

    • Inquiry period: extended from 60 days under the 2005 regulation to 90 days.
    • Investigation period: extended from 120 days under the 2005 regulation to 180 days.

    It also formalises a new pre-inquiry “institutional assessment” stage (§93.306), in which the Research Integrity Officer must document whether an allegation falls within the misconduct definition and PHS jurisdiction before an inquiry is opened — with no fixed time limit for this new stage. The rule further clarifies confidentiality obligations, allowing institutions to disclose respondent identities to journals, co-authors, and collaborating institutions where there is a legitimate need to know, and expands provisions covering multiple respondents and multi-institution proceedings.

    Frequently Asked Questions

    Does the Funding Agency Investigate Misconduct Directly, or Does the Institution?

    The institution conducts the initial inquiry and investigation, not the federal funding agency. Agencies such as ORI or the NSF OIG monitor the case, can intervene if the institution is unable or unwilling to act, and retain authority over the grant throughout.

    What Standard of Proof Applies to a Misconduct Finding?

    A finding requires proof “by a preponderance of the evidence” — more likely than not — not the criminal “beyond a reasonable doubt” standard. The conduct must also be shown to have been committed intentionally, knowingly, or recklessly, and to represent a significant departure from accepted research practice.

    What Is the First Phase of a Research Misconduct Response?

    The process begins with an institutional assessment or inquiry — a preliminary review to decide whether an allegation has enough substance to warrant a full investigation. Under the 2024 Final Rule, this assessment stage is now formally documented before any inquiry clock starts running.

    To Whom Does the Federal Research Misconduct Policy Apply?

    The policy applies to anyone proposing, performing, or reviewing federally funded research — including applicants, grant recipients, subrecipients, project participants, and peer reviewers — at any institution receiving Public Health Service or comparable federal research funding.

    Implications for Research Administrators

    The practical exposure is threefold: a live award can be frozen or restricted mid-project, cost recovery can claw back funds already spent, and delayed or incomplete notification to the funder is a compliance failure in its own right, separate from the underlying allegation. Research integrity offices should treat the 2026 compliance deadline as a trigger to audit their policies against the extended 90/180-day timelines and the new institutional-assessment stage — a policy still reflecting the 2005 regulation’s 60/120-day clock no longer matches what ORI expects in an institutional record.

    The Final Rule’s added reporting elements — sequestration inventories, interview transcripts, and multi-institution coordination — point toward longer, more paperwork-intensive proceedings even as deadlines extend. For anyone administering federally funded research, what happens to the grant while a case runs is as important as the underlying definition of misconduct itself.

  • GMC Research Misconduct: Process Explained

    When the General Medical Council (GMC) investigates a doctor for research misconduct, it runs a fitness-to-practise process, not a scientific-integrity audit — assessing whether conduct such as data fabrication, falsification, plagiarism, undisclosed conflicts, or dishonesty means the doctor’s registration should be restricted, suspended, or removed. That process is legally and procedurally distinct from the research-governance route run through NHS trusts and the Health Research Authority.

    GMC research misconduct describes conduct by a UK-registered doctor — fabricating or falsifying research data, plagiarism, or a serious breach of the GMC’s Good practice in research standards — that the GMC investigates through its statutory fitness-to-practise procedure to decide whether registration should be restricted. This article maps that regulatory pathway, distinct from the NHS governance process covered elsewhere on this site.

    What counts as research misconduct under GMC guidance?

    The GMC’s Good practice in research guidance — supplementary to Good medical practice — sets the standards doctors must meet when designing, organising, or carrying out research in the UK. It requires doctors to conduct research “honestly and with integrity” and to “report evidence of financial or scientific fraud, or other failures to follow the requirements of the UK Policy Framework, to an appropriate person in your employing or contracting organisation and relevant regulatory bodies.”

    In practice, conduct that can trigger a GMC concern includes:

    • Fabricating or falsifying research data or results
    • Plagiarism, or misattributing authorship and contribution
    • Failing to obtain or properly document informed consent from participants
    • Undeclared financial or commercial conflicts of interest
    • Proceeding without required research ethics committee or Health Research Authority approval
    • Dishonesty in reporting, publishing, or communicating research findings

    Not every departure from the guidance is treated as serious. The GMC’s threshold is whether the conduct raises a genuine question about the doctor’s fitness to practise — a public-protection test, not a general research-quality assessment.

    How does a GMC investigation into research misconduct work?

    A GMC fitness-to-practise investigation follows a defined sequence, whether the concern is clinical or research-related.

    1. Triage and provisional enquiry. The GMC receives a complaint — from a patient, colleague, employer, journal, whistleblower, or another regulator — and screens it against its threshold criteria for fitness-to-practise concerns.
    2. Full investigation and Rule 7 letter. If the threshold is met, a case officer gathers evidence — research data, protocols, correspondence, expert reports — and the doctor is formally notified of the allegation and invited to respond in writing under Rule 7 of the General Medical Council (Fitness to Practise) Rules 2004.
    3. Case examiner decision. Since reforms took effect in October 2015, two case examiners — one medical, one lay — review the completed investigation. They can close the case, issue a warning, agree undertakings with the doctor, or refer the matter to a full hearing.
    4. Interim Orders Tribunal (IOT). Where there is an immediate risk to patients or public confidence, the GMC can refer a doctor to an Interim Orders Tribunal at any stage, which can suspend or restrict practice while the investigation continues.
    5. Medical Practitioners Tribunal Service (MPTS) hearing. Contested or serious cases proceed to a public hearing before the MPTS — the tribunal function that has operated as structurally separate from the GMC’s investigative arm since the Health and Social Care Act 2012 — which determines the facts and whether fitness to practise is impaired.

    Timescales vary considerably. Straightforward cases can close within months of the initial complaint; research-misconduct allegations involving data audits, statistical experts, and multiple witnesses commonly take a year or longer before a tribunal hearing is listed.

    How does GMC oversight differ from other UK research-integrity bodies?

    A common misunderstanding is that the GMC is the primary body for adjudicating research misconduct. It is not: the GMC’s jurisdiction is limited to whether an individual doctor’s registration should be affected. Separate bodies handle research governance, publication integrity, and institutional investigation — often before, or without, GMC involvement.

    Body Role Typical trigger Possible outcome
    GMC / MPTS Regulates individual doctors’ fitness to practise Allegation of dishonesty, fraud, or serious breach of Good practice in research Warning, conditions, suspension, erasure
    Health Research Authority (HRA) Approves and oversees research governance under the UK Policy Framework for Health and Social Care Research Non-compliance with ethics approval, consent, or protocol Withdrawal of approval; referral to sponsor or regulator
    Employing NHS trust or university First-line investigator under institutional research-governance policy Any internal concern or whistleblower report Internal disciplinary action; referral to GMC/HRA
    Committee on Publication Ethics (COPE) Advises journals on handling integrity concerns in published work Concern about a specific paper Correction, expression of concern, retraction
    UK Research Integrity Office (UKRIO) Independent advisory body on research integrity practice Institutions seeking independent panel members or advice Advisory report to the commissioning institution

    These routes run in parallel. A university may investigate authorship and data-integrity questions — closer to the authorship contribution disputes handled through institutional and publisher channels — while separately reporting a doctor to the GMC if dishonesty or patient safety is in issue. The GMC does not duplicate a university’s or journal’s fact-finding; it relies on it as evidence.

    What sanctions can follow a finding of research misconduct?

    If an MPTS tribunal finds a doctor’s fitness to practise impaired because of research misconduct, it must select from a defined range of sanctions, applying the principle that the overriding objective is public protection and public confidence in the profession — not punishment of the doctor.

    • No further action — exceptional, where impairment is minor and already remediated
    • Warning — a formal recorded statement that conduct fell below the expected standard
    • Undertakings — voluntary, monitored commitments agreed with the doctor
    • Conditions on registration — for example, mandatory supervision of any future research activity
    • Suspension — time-limited removal of the right to practise
    • Erasure — removal from the medical register, the most severe outcome

    Erasure is the outcome most associated with persistent or serious dishonesty. In May 2010, a GMC fitness-to-practise panel found Andrew Wakefield guilty of dishonesty and serious ethical failings in the research underlying his 1998 Lancet paper linking the MMR vaccine to autism; he was erased from the medical register, and The Lancet formally retracted the paper the same year. The case remains the most cited illustration of how a research-integrity failure can translate directly into a fitness-to-practise sanction.

    Answer-first Q&A on GMC research misconduct

    What is misconduct in GMC cases?

    Under GMC processes, misconduct is any act or omission that falls short of the standards set out in Good medical practice and, for researchers, Good practice in research. Not every shortfall is serious; the GMC investigates only conduct grave enough to raise a genuine fitness-to-practise concern.

    What are the three types of research misconduct?

    Research-integrity frameworks generally group misconduct into three core categories: fabrication (inventing data), falsification (manipulating data or results), and plagiarism (using others’ work without attribution). GMC cases frequently add a further concern — undisclosed conflicts of interest — where dishonesty is also alleged.

    How long does a GMC investigation take?

    Length varies with complexity. Straightforward complaints can close within months, but research-misconduct investigations involving expert data review, multiple witnesses, and possible MPTS hearings commonly extend beyond a year before a tribunal date is set.

    What are the GMC’s core ethical domains?

    The GMC’s Good medical practice framework, which underpins every fitness-to-practise judgment, is organised around domains covering knowledge and professional development, patient partnership and communication, safety and quality, and trust and professionalism — the same domains applied when a research-conduct concern is assessed.

    What this means for institutions and individual researchers

    For research administrators, the practical implication is sequencing: internal research-governance and HRA-facing processes should establish the facts first, with a GMC referral triggered where dishonesty, patient safety, or public confidence is engaged — not as a substitute for institutional investigation. For doctor-researchers, Good practice in research compliance is not a separate track from clinical professionalism: a breach in the research context is assessed against the same fitness-to-practise standard as a clinical failing, and can carry the same range of sanctions, up to erasure.

    As UK research governance tightens around transparency and conflict-of-interest declarations, doctors involved in research should expect institutional reporting obligations to the GMC to be treated as a normal, not exceptional, part of research oversight.

  • Research Misconduct Allegation Phases (3 Stages)

    A research misconduct allegation moves through three formal stages — inquiry, investigation and adjudication — each with a distinct purpose, evidentiary threshold and, under the US federal model, a defined deadline. The inquiry screens whether a full investigation is warranted; the investigation builds a factual record; adjudication delivers the finding and any sanctions. This article walks through each phase in order, then contrasts the US federal timetable with the more variable UK institutional model.

    Research misconduct is formally defined, under the US Public Health Service policy (42 C.F.R. Part 93), as fabrication, falsification, or plagiarism in proposing, performing, or reviewing research, or in reporting research results — a definition that explicitly excludes honest error and legitimate differences of scientific opinion.

    What Is a Research Misconduct Allegation?

    A research misconduct allegation is a formal statement, made by a complainant to a designated institutional official — typically a Research Integrity Officer (RIO) — that a named respondent has fabricated, falsified or plagiarised research. The allegation triggers a duty on the institution to make a preliminary assessment before any formal phase begins. This assessment is not itself one of the three formal phases; it simply determines whether the allegation, if true, would fall within the scope of research misconduct.

    Phase One: The Inquiry

    The inquiry is a preliminary, confidential fact-check, not a determination of guilt. Its sole question is whether the allegation has enough substance to warrant a full investigation.

    • A small committee or designated official gathers documents and research records.
    • The respondent and complainant may be interviewed informally.
    • A written inquiry report records the findings and a recommendation on whether to proceed.

    Under 42 C.F.R. §93.307(g), US institutions receiving Public Health Service funding must complete the inquiry within 60 calendar days of initiation unless the delay is documented and justified. If the inquiry finds no substance to the allegation, the matter closes at this point; the majority of allegations do not proceed past inquiry.

    Phase Two: The Investigation

    If the inquiry concludes an investigation is warranted, the process becomes formal. The respondent is notified in writing, and under federal guidance the institution must notify the Office of Research Integrity (ORI) within 30 days of that determination.

    The investigation committee, typically composed of subject-matter experts without conflicts of interest, must establish three things:

    1. Whether there was a significant departure from accepted practices in the relevant field.
    2. Whether the conduct was committed intentionally, knowingly, or recklessly.
    3. Whether the allegation is proven by a preponderance of the evidence — the standard set out in 42 C.F.R. §93.106, a lower bar than criminal “beyond reasonable doubt.”

    US institutions are expected to complete the investigation within 120 days of initiation, covering evidence review, interviews, drafting the report, and giving the respondent an opportunity to comment, per 42 C.F.R. §93.311. Extensions are routinely requested and granted where cases are complex.

    Phase Three: Adjudication

    Adjudication is the decision phase. An institutional Deciding Official — someone who played no role in the inquiry or investigation — reviews the investigation report, the respondent’s comments, and any procedural objections, then issues a final institutional finding.

    Where federal funding is involved, ORI conducts its own oversight review of the institution’s finding before any Public Health Service administrative action is imposed. According to ORI’s own published process, a respondent facing formal action retains the right to request a hearing before an Administrative Law Judge before sanctions take effect. Possible outcomes range from correction of the research record to debarment from federal funding and referral for further action.

    How Do UK and US Procedures Compare?

    The US model is unusual in having a single statutory timetable enforced through 42 C.F.R. Part 93. The UK has no equivalent statutory regulator; instead, individual institutions run their own codes of practice, informed by non-binding sector guidance.

    Feature United States (PHS-funded research) United Kingdom
    Governing instrument 42 C.F.R. Part 93 Institutional codes of practice, informed by UKRIO and UKRI guidance
    Federal/national oversight body Office of Research Integrity (ORI) None statutory; UK Research Integrity Office (UKRIO) is advisory
    Inquiry deadline 60 calendar days Not centrally mandated; varies by institution
    Investigation deadline 120 calendar days Not centrally mandated; varies by institution
    Final appeal route Hearing before an Administrative Law Judge Institutional appeal stage (naming varies, e.g. “Stage 3”)

    UKRI’s April 2025 guidance for research organisations describes an assessment stage that “refers to the process of reviewing the nature of an allegation of research misconduct” and establishing scope — functionally equivalent to the US inquiry, but without a fixed clock. UK institutional codes, such as those published by the University of Surrey and University of Staffordshire, typically layer a similar inquiry-investigation-decision logic across numbered stages, though the labelling and timeframes differ institution to institution. This is separate from journal-level handling: COPE’s flowcharts guide editors on suspected misconduct in submitted or published papers, and a publisher may pause or flag a work while the institutional process above runs in parallel.

    Answer-First Questions About Misconduct Allegations

    What are the phases of a research misconduct allegation?

    The formal process runs through three phases: an inquiry that screens whether an allegation has substance, an investigation that establishes the facts against a defined evidentiary standard, and adjudication, where a Deciding Official issues the final finding and any sanctions.

    What is the first phase in response to a research misconduct allegation?

    The first formal phase is the inquiry — a confidential, preliminary review of documents and testimony conducted to determine whether the allegation warrants a full investigation. It is not a determination of wrongdoing and, under US federal policy, must normally conclude within 60 days.

    Who investigates allegations of research misconduct?

    The employing or funded institution conducts the inquiry and investigation, typically through a Research Integrity Officer and an appointed committee of subject experts. For US federally funded research, the Office of Research Integrity then reviews the institution’s finding before any federal sanction is applied.

    What is a research misconduct allegation?

    A research misconduct allegation is a formal claim that a named individual has fabricated, falsified, or plagiarised research. It excludes honest error or genuine scientific disagreement, and it obliges the receiving institution to make a documented preliminary assessment before any formal phase begins.

    Implications and Next Steps

    For research administrators, the practical lesson is procedural discipline: documenting the preliminary assessment, meeting inquiry and investigation deadlines where they apply, and keeping the Deciding Official separate from earlier stages protects the institution against later appeal. For researchers named as respondents, understanding which phase they are in — and what standard of proof applies — clarifies what rights and evidence obligations attach at each step.

    As UK institutions continue to align local codes with UKRI’s 2025 guidance, expect greater convergence in stage naming, though a single UK statutory deadline regime, of the kind ORI enforces in the US, remains absent. Institutional research administration teams should treat the inquiry-investigation-adjudication sequence as the baseline procedural map, then check their own code of practice for the specific labels and timeframes that apply locally.

  • Research Misconduct Lawyer: Do You Need One?

    A research misconduct lawyer is a solicitor, barrister, or (in the US) an attorney who advises a researcher through an allegation of fabrication, falsification, or plagiarism — from the initial screening through formal investigation, any disciplinary hearing, and appeal. Legal counsel becomes advisable once an allegation is put in writing, and becomes necessary where funding, employment, professional registration, or a potential fraud referral is at stake.

    Research misconduct is fabrication, falsification, or plagiarism in proposing, performing, or reviewing research, or in reporting research results — a definition set out in US federal regulation and mirrored across UK institutional policies aligned to the Concordat to Support Research Integrity. Honest error and legitimate differences of scientific opinion are explicitly excluded.

    Do you need a research misconduct lawyer?

    Not every allegation requires a lawyer. A colleague’s informal query about a figure in a preprint, resolved by sending the underlying data, rarely needs legal input. A written allegation that triggers a formal screening or inquiry under an institution’s misconduct procedure is a different matter entirely.

    Engage counsel as soon as any of the following applies:

    • The allegation has been formally logged and a named investigation or inquiry panel has been convened.
    • Federal or funder money is involved, raising the possibility of debarment, clawback, or a fraud referral.
    • The outcome could affect employment status, tenure, or professional registration.
    • The institution’s own HR or disciplinary process is running in parallel with the research-integrity process.
    • Findings, if upheld, would likely require retraction of published work or notification to a journal or funder.

    A research misconduct lawyer does not replace the institution’s own procedure. Their role is to make sure that procedure is followed correctly, that evidence is preserved and properly interpreted, and that the respondent’s side of the record is documented at every stage — screening, inquiry, investigation, and any appeal.

    What happens during a research misconduct investigation?

    Most frameworks — UK and US alike — separate a misconduct case into a preliminary screening stage and a fuller inquiry, followed by a formal investigation and an appeal if findings are contested. The exact labels and thresholds differ by jurisdiction and by institution, which is itself a source of confusion for respondents.

    In the UK, there is no single statutory regulator equivalent to the US Office of Research Integrity (ORI). Each research organisation runs its own procedure, historically modelled on the UK Research Integrity Office (UKRIO) template. UKRIO’s 2023 publication, Procedure for the Investigation of Misconduct in Research, was formally sunset and replaced in December 2025 by a revised document titled Detailed procedure for investigating breaches of research integrity — a change institutional policy owners should check their references reflect. UK Research and Innovation (UKRI) also published dedicated guidance for research organisations on investigating research misconduct in April 2025, which states that institutional procedures “should be developed and reviewed in light of, and be consistent with, the Concordat to Support Research Integrity.”

    In the US, misconduct involving Public Health Service-funded research is governed by federal regulation at 42 CFR Part 93, which sets a three-stage process of inquiry, investigation, and adjudication, with ORI oversight and a defined right of appeal.

    Aspect US (PHS/ORI-funded research) UK (institution-led)
    Governing framework 42 CFR Part 93; ORI oversight No single regulator; institutional procedures aligned to the Concordat to Support Research Integrity and UKRI guidance
    Typical phases Inquiry → investigation → adjudication → appeal Screening → inquiry/initial assessment → formal investigation → appeal
    Standard of proof Preponderance of the evidence Balance of probabilities (the standard civil test used across most institutional procedures)
    Right to be accompanied Institution-dependent; counsel’s role at interviews is often advisory only Statutory right to be accompanied at a formal disciplinary hearing (Employment Relations Act 1999)

    The practical consequence for a respondent is definitive: know which framework applies to your case before assuming what your lawyer can and cannot do in the room.

    What rights does a respondent have?

    Due process protections for an accused researcher exist precisely because a misconduct finding can end a career. A fair procedure gives the respondent the opportunity to see and answer the case against them before any finding is made.

    Core respondent rights typically include:

    • Written notification of the specific allegations and the evidence supporting them.
    • A named point of contact and a reasonable timeframe to prepare a response.
    • The opportunity to submit evidence, nominate witnesses, and comment on a draft report before it is finalised.
    • Confidentiality of the process, so far as is consistent with a fair and thorough investigation.
    • A right of appeal against adverse findings or disproportionate sanctions.

    In the UK, employees have a statutory right under the Employment Relations Act 1999 to be accompanied at a formal disciplinary hearing by a colleague or trade union representative; a legal representative is not automatic and depends on the institution’s own procedure and the seriousness of the case. This is a materially different arrangement from many US institutional processes, where legal counsel may attend interviews but is frequently restricted to an advisory role rather than direct advocacy before the panel.

    Whose responsibility is it to report misconduct?

    Under the Concordat to Support Research Integrity, responsibility for identifying and reporting suspected research misconduct is shared, not delegated to a single office. Researchers, supervisors, co-authors, and institutions each carry a duty to raise a genuine concern through the correct channel rather than resolve it informally or ignore it.

    This shared-responsibility model has a direct consequence for anyone accused: the person who raised the concern may be a co-author, a journal editor acting on a reader’s tip, a funder’s compliance team, or an internal whistleblowing route — each of which triggers a different entry point into the institution’s procedure, and each of which a research misconduct lawyer will want identified early, since it shapes what evidence already exists before the respondent is even notified.

    Common questions about research misconduct allegations

    Who investigates allegations of research misconduct?

    In the UK, the employing research organisation investigates, typically through an inquiry panel or investigation committee constituted under its own procedure. In the US, institutions conduct the inquiry and investigation, with the federal Office of Research Integrity overseeing PHS-funded research and adjudicating contested findings.

    What counts as research misconduct?

    Research misconduct is fabrication, falsification, or plagiarism in proposing, conducting, reviewing, or reporting research. Some institutional frameworks add serious deviation from accepted practice or failure to secure required ethical approvals, but honest error and legitimate differences of scientific opinion are explicitly excluded from every recognised definition.

    What is considered the most serious form of research misconduct?

    Fabrication — inventing data outright — and falsification — manipulating materials, equipment, or data so the record is inaccurate — are generally treated as the most serious categories, because they corrupt the research record itself rather than misattributing credit, which is the harm caused by plagiarism.

    Whose responsibility is it to identify and report research misconduct?

    Under the UK’s Concordat to Support Research Integrity, every researcher, supervisor, and institution shares responsibility for identifying and reporting suspected misconduct. There is no single national regulator, so each employer’s own procedure — typically aligned to UKRI guidance — governs how, and to whom, a concern must be formally raised.

    For an accused researcher, the practical implication of all this is straightforward: engage legal counsel as soon as a formal allegation exists, confirm which procedural framework governs the case, and insist on the written notice, response time, and appeal rights that framework guarantees. As UKRIO’s December 2025 procedure revision and UKRI’s 2025 guidance both illustrate, the rules themselves continue to evolve — a respondent’s best protection is a lawyer who tracks which version currently applies, not the version that applied when the institution’s policy was last printed.

    For related definitions and process context, see the CASRAI Dictionary and the broader research administration resource hub.

  • Stanford President Research Misconduct Timeline

    Marc Tessier-Lavigne resigned as Stanford University president on 19 July 2023, days after a Special Committee-commissioned scientific panel completed a seven-month review of 12 papers he had co-authored. The panel found repeated data manipulation in laboratories he ran but cleared him of personally falsifying data. His stanford president research misconduct case remains one of the clearest recent examples of a university running a named, transparent misconduct review to its conclusion.

    Research misconduct, as defined by the US Office of Research Integrity, is “fabrication, falsification, or plagiarism in proposing, performing, or reviewing research, or in reporting research results.” Stanford’s inquiry into its own president tested that definition against a public figure, under public scrutiny, in real time — which is what makes its process, rather than its verdict alone, instructive for research administrators.

    What Triggered the Stanford Research Misconduct Investigation?

    The trigger was student journalism, not an internal audit. On 29 November 2022, The Stanford Daily, reported by then-freshman Theo Baker, published allegations that several papers co-authored by Tessier-Lavigne contained manipulated images, drawing on critiques that had circulated anonymously on the post-publication review site PubPeer since 2015.

    The same week, The EMBO Journal confirmed it had separately opened its own inquiry into a 2008 paper Tessier-Lavigne co-authored — a detail largely absent from mainstream coverage of the case, and a reminder that journal-level scrutiny and institutional review are distinct, parallel tracks that do not wait on each other.

    How Did Stanford’s Special Committee Investigate the Allegations?

    Stanford’s Board of Trustees announced in December 2022 that a Special Committee would review the claims. It appointed Mark Filip, a former federal judge and partner at Kirkland & Ellis, to lead the fact-finding, supported by a five-member scientific panel: Hollis Cline (Scripps Research), Kafui Dzirasa (Duke University), Steven Hyman (Harvard University, provost emeritus), Randy Schekman (UC Berkeley, former editor-in-chief of PNAS), and Shirley Tilghman (Princeton University, former president).

    Between roughly January and June 2023, the panel examined 12 papers, interviewed lab members and co-authors, and reviewed underlying research data rather than relying on published figures alone — a distinction that matters because most disputed images had already passed peer review once.

    Date Event
    2015 onward Anonymous image-manipulation critiques accumulate on PubPeer
    29 Nov 2022 Stanford Daily publishes first report; EMBO Journal opens a parallel inquiry
    Dec 2022 Board of Trustees announces a Special Committee review
    Jan–Jun 2023 Mark Filip and a five-member scientific panel investigate 12 papers
    17 Jul 2023 Panel delivers 95-page final report to the Board
    19 Jul 2023 Tessier-Lavigne announces resignation, effective 31 Aug 2023
    31 Aug 2023 Resignation takes effect; Richard Saller becomes interim president
    4 Apr 2024 Jonathan Levin named Stanford’s 13th president
    1 Aug 2024 Levin assumes office

    What Did the Scientific Panel’s Report Conclude?

    The panel’s 95-page report, released on 17 July 2023, concluded that laboratories Tessier-Lavigne ran had engaged in “manipulation of research data” across several papers, and that he was principal author on five of the 12 papers reviewed. It found no evidence he personally fabricated or falsified data, but concluded he had not taken sufficiently decisive steps to correct the scientific record once problems were flagged.

    Following the report, Tessier-Lavigne said he intended to retract at least three papers and correct two more, all originally published between 1999 and 2009 — before his Stanford presidency began. Two papers were formally retracted from Science on 31 August 2023, according to Retraction Watch.

    • 12 co-authored papers examined by the scientific panel
    • 5 papers on which Tessier-Lavigne was principal author
    • At least 3 papers slated for retraction, 2 for correction
    • 1999–2009: publication window for the papers in question

    The Resignation Timeline: From Report to Successor

    Tessier-Lavigne announced his resignation on 19 July 2023, two days after receiving the panel’s findings, saying Stanford needed a president “whose leadership is not hampered by such discussions.” The resignation took effect on 31 August 2023, ending a seven-year presidency.

    Richard Saller, a classicist and former Stanford provost, served as interim president from September 2023. Stanford’s trustees named Jonathan Levin, dean of the Graduate School of Business, as the university’s 13th president on 4 April 2024; Levin assumed office on 1 August 2024 — just over a year after the resignation was announced.

    Answer-First Q&A on the Tessier-Lavigne Case

    When did Marc Tessier-Lavigne resign as Stanford president?

    Marc Tessier-Lavigne announced his resignation on 19 July 2023, two days after Stanford’s Special Committee released its scientific panel’s final report. His resignation took effect on 31 August 2023, and Richard Saller became interim president the same day.

    What did Stanford’s investigation find about the research?

    The scientific panel found that laboratories Tessier-Lavigne led had engaged in repeated data manipulation across several papers examined, out of 12 reviewed in total. It attributed the manipulation to others in the labs, not to Tessier-Lavigne personally, but faulted his oversight and slow correction of the record.

    Was Tessier-Lavigne found to have committed research misconduct himself?

    No. The panel cleared Tessier-Lavigne of personally fabricating or falsifying data. It concluded he was unaware of the manipulation at the time of publication but should have acted more decisively once concerns were raised, particularly regarding papers on which he was principal author.

    What counts as research misconduct under research-integrity standards?

    Research misconduct is generally defined as fabrication, falsification, or plagiarism in proposing, performing, or reporting research — the definition used by the US Office of Research Integrity. Authorship disputes, honest error, and differences of scientific judgement are explicitly excluded from this definition.

    Implications for Institutional Research-Integrity Response

    The Tessier-Lavigne case is a rare instance where a governing board investigated its own chief executive using outside legal counsel and a named, independent scientific panel, then published the resulting report in full. That combination — external fact-finders, disclosed panel membership, and a public report — is closer to the process integrity that bodies such as the Committee on Publication Ethics (COPE) recommend for misconduct investigations than the closed-door reviews typical of many institutions.

    For research administrators, the case demonstrates that reputational and governance consequences can follow from oversight failures even where personal fabrication is not established. It also shows that journal-level inquiries (EMBO Journal) and institutional inquiries can run in parallel without either resolving the other, meaning research administration teams should track both tracks rather than treating a clean institutional finding as the final word. A decade-old PubPeer thread, in this case, outlasted the papers’ authors’ careers before triggering formal review — underscoring why routine, proactive image-integrity screening matters more than reactive response once allegations become public.

  • Francesca Gino Research Misconduct Case Study

    The Francesca Gino research misconduct case is the 2021–2025 dispute in which Harvard Business School investigated, and ultimately dismissed, a tenured professor after concluding she had fabricated data in four published studies — a process that also produced a $25 million lawsuit, a Harvard countersuit, and one of the rare tenure revocations in the university’s modern history.

    Research misconduct, in the definition used by US federal policy and echoed by bodies such as the Committee on Publication Ethics (COPE), is the fabrication, falsification, or plagiarism of data in proposing, performing, or reviewing research. The Gino case is unusual not for the underlying allegation but for how visible the institutional machinery became: an 18-month internal inquiry, a 1,200-page report, a public unsealing order, and two overlapping lawsuits that together offer a rare, document-level view of how one major research university actually runs a misconduct investigation.

    What is the Francesca Gino research misconduct case?

    Francesca Gino was the Tandon Family Professor of Business Administration at Harvard Business School, where her research on honesty and ethical behaviour made her one of the most cited figures in behavioural science. Concerns about her data first surfaced around 2020, when a doctoral student’s replication attempt failed to reproduce a widely publicised Gino networking study. That failure led to a wider audit that eventually implicated four separate papers.

    Harvard’s internal investigation committee — three senior Harvard Business School faculty, assisted by an outside forensic firm — concluded that Gino had committed research misconduct intentionally, knowingly, or recklessly. The university placed her on unpaid administrative leave in June 2023 and, in May 2025, revoked her tenure and ended her employment before her two-year suspension had even run its course.

    How did Harvard’s misconduct investigation unfold?

    The Gino case shows a misconduct investigation moving through distinct, document-traceable stages rather than a single disciplinary event. Each stage generated its own record, several of which later became public through litigation.

    • 2020–2021: Doctoral candidate Zoé Ziani fails to replicate a Gino personal-networking study and raises concerns internally.
    • Autumn 2021: The Data Colada team — Uri Simonsohn, Leif Nelson, and Joseph Simmons — contacts Harvard Business School about anomalies in four Gino papers.
    • 2021–2023: Harvard conducts an internal investigation described by the HBS dean as an “18-month” process, producing a 1,200-page report under Case RI21-001.
    • June 2023: HBS places Gino on unpaid administrative leave; Data Colada simultaneously publishes its “Data Falsificada” blog series detailing the alleged anomalies.
    • August 2023: Gino files a $25 million lawsuit against Harvard, HBS Dean Srikant Datar, and the three Data Colada researchers, alleging defamation and gender discrimination.
    • March 2024: Judge Myong J. Joun orders the unsealing, with redactions, of Harvard’s 1,200-page investigation report.
    • September 2024: The court dismisses Gino’s defamation and privacy claims against both Harvard and the Data Colada defendants in full; breach-of-contract and gender-discrimination claims are allowed to proceed.
    • May 2025: The Harvard Corporation revokes Gino’s tenure and terminates her employment.
    • September 2025: Harvard sues Gino for defamation, alleging she submitted a falsified dataset to the university during the dispute.

    Notably, under US federal research-integrity rules, the Office of Research Integrity (ORI) only has jurisdiction over misconduct in Public Health Service-funded research. Much of Gino’s behavioural-science work fell outside that remit, meaning the entire investigation design — committee composition, evidentiary standard, and appeal rights — was governed solely by Harvard’s own internal policy rather than a codified federal or funder-mandated process.

    What evidence did investigators find in the retracted papers?

    Four papers sit at the centre of the case. All four have since been retracted, though the first was flagged for an unrelated data issue before the wider investigation began.

    Paper Journal Year published Retraction status
    “Signing at the beginning makes ethics salient…” (Shu, Mazar, Gino, Ariely, Bazerman) Proceedings of the National Academy of Sciences 2012 Retracted September 2021
    “Evil Genius? How Dishonesty Can Lead to Greater Creativity” (Gino, Wiltermuth) Psychological Science 2014 Retracted 2023
    “The Moral Virtue of Authenticity…” (Gino, Kouchaki, Galinsky) Psychological Science 2015 Retracted 2023
    “Why Connect? Moral Consequences of Networking…” (Gino, Kouchaki, Casciaro) Journal of Personality and Social Psychology 2020 Retracted 2023

    According to Harvard’s unsealed report, Gino offered investigators two explanations for the data irregularities: honest error by her or her research assistants, or tampering by a malicious third party with access to her files. The committee found neither explanation plausible, writing that her “repeated and strenuous argument” for a bad-actor scenario across four separate studies undermined the credibility of her broader testimony.

    A separate, self-organised accountability effort — the Many Co-Authors Project — later reviewed 56 papers naming Gino as involved in data collection. Its contributors reported that for roughly 60% of those papers, responding co-authors said they had never had access to the underlying raw data, a data-provenance gap that goes beyond the four papers formally retracted.

    What happened in the Gino v. Harvard litigation?

    Litigation is what made this a document-level case study rather than a private disciplinary matter. Gino’s August 2023 suit sought $25 million and alleged defamation, gender discrimination under Title IX, and breach of contract. Harvard’s decision to submit its full 1,200-page report as court evidence — and a subsequent judicial order to unseal it — meant the investigative record itself became a matter of public record, rather than remaining confidential under standard university misconduct procedure.

    Did Harvard sue Francesca Gino for defamation?

    Yes. In September 2025, Harvard filed its own defamation suit against Gino, alleging she submitted a falsified dataset to the university in an attempt to prove she had not committed data fraud. This followed her original 2023 defamation claim against Harvard, which a federal judge dismissed in September 2024.

    Does Francesca Gino still work at Harvard?

    No. The Harvard Corporation, the university’s top governing board, revoked Gino’s tenure and terminated her employment in May 2025, ending her unpaid suspension before it was due to expire. Harvard described tenure revocation as an extremely rare step not used at the institution for decades.

    Did Harvard revoke Francesca Gino’s tenure over falsifying data allegations?

    Yes. Harvard’s investigation committee, made up of three senior HBS faculty, concluded after an 18-month inquiry that Gino had committed research misconduct “intentionally, knowingly, or recklessly,” a finding that directly preceded the termination proceedings completed in 2025.

    What does the case reveal about institutional misconduct processes?

    For research administrators, the Gino case is less a story about one professor than a stress test of how an elite institution structures a misconduct inquiry when there is no external regulator compelling a specific procedure. Several implications stand out.

    • Investigation length is a real institutional risk. An 18-month internal inquiry, followed by two further years of litigation before a final personnel decision, shows how misconduct cases without a codified stage-gate process (unlike, for example, COPE’s published flowcharts) can extend for years and generate parallel legal exposure.
    • Confidentiality and public interest can collide. Harvard initially treated its 1,200-page report as confidential; a court order — not university policy — forced its unsealing. Institutions relying purely on internal confidentiality norms should anticipate that litigation can override them.
    • Peer self-auditing is emerging as a parallel accountability layer. The Many Co-Authors Project shows co-authors organising their own data-provenance review independently of the university process, filling a gap that formal institutional investigation did not cover at scale.
    • Whistleblower exposure has financial consequences. Data Colada’s team faced personal litigation risk for reporting anomalies, prompting outside researchers to crowdfund legal costs — a chilling-effect dynamic that institutional research-integrity policy rarely addresses directly.

    Frameworks such as the UK’s Concordat to Support Research Integrity and COPE’s core practices exist precisely to standardise the stages this case worked through ad hoc: initial concern, preliminary assessment, formal investigation, evidentiary report, and sanction. Institutions without an equivalent codified process should expect that, absent clear stage-gates, a misconduct case can default to years of litigation to resolve what a documented procedure might settle in months.

    The case remains open in part: Gino’s breach-of-contract and gender-discrimination claims against Harvard, and Harvard’s own defamation suit against Gino, were both still active as of late 2025. The eventual rulings will further shape how far US courts are willing to scrutinise a university’s internal misconduct-investigation process.

    For broader context on how institutions structure research-integrity roles and terminology, see CASRAI’s research administration resources and the CASRAI Dictionary.

  • Image Manipulation as Research Misconduct

    Image manipulation as research misconduct means altering a figure — micrograph, blot, gel, or scan — so it misrepresents the underlying data; under the US Office of Research Integrity (ORI) and most institutional policies this falls under falsification, one of the three FFP misconduct categories. Forensic screening tools now flag duplication, splicing, and, increasingly, AI-generated fabrication before publication.

    Image manipulation is the alteration of a scientific image — through cloning, splicing, selective erasure, or generative synthesis — in a way that changes the scientific meaning of the data it depicts. Not every edit is misconduct: adjustments to brightness, contrast, or colour balance applied uniformly across an entire image are generally acceptable, provided they do not obscure, eliminate, or misleadingly enhance specific features. The distinction was first codified by Mike Rossner and Kenneth Yamada in a widely cited 2004 Journal of Cell Biology editorial, which remains the reference framework cited by UKRIO, ORI, and most publisher guidelines today.

    What Counts as Image Manipulation in Research Misconduct?

    Research-integrity bodies distinguish acceptable image processing from misconduct by asking a single question: does the resulting image still accurately represent the original data? Acceptable adjustments are applied uniformly, disclosed, and do not change scientific meaning. Unacceptable manipulations — the kind that constitute misconduct — include:

    • Cloning or duplicating a band, cell, or region within the same image or across different figures without disclosure
    • Splicing separate gel or blot lanes together and presenting them as one continuous exposure
    • Selectively erasing or adding features (bands, cells, particles) to support a claimed result
    • Non-uniform adjustment of brightness, contrast, or colour that obscures or exaggerates specific data points
    • Reusing an image from an unrelated experiment and relabelling it as a different condition

    ORI’s own reference guidance, distributed as an infographic to US research institutions, sets out these categories explicitly and has become the de facto training standard cited by UK and European research-integrity offices, including the UK Research Integrity Office (UKRIO).

    Why Do Research-Integrity Bodies Treat Manipulated Images as Misconduct?

    Image manipulation is classified as falsification, not fabrication, when an underlying experiment did take place but its visual record has been altered to misrepresent the result. The distinction matters for investigation and sanction, but the practical effect is the same: the published record no longer reflects what was actually observed.

    The scale of the problem is well documented. A landmark 2016 study in mBio by Elisabeth Bik, Arturo Casadevall, and Ferric Fang screened 20,621 papers published between 1995 and 2014 and found problematic figures in 3.8% of them, with roughly one in twenty-five showing duplication and about 0.3% showing clear evidence of deliberate manipulation rather than honest error. That single study reframed image screening from a niche editorial concern into a routine publisher workflow requirement.

    How Do Forensic Screening Tools Detect Fabricated or Duplicated Images?

    Detection now runs on three layers: manual visual review, software-assisted forensic analysis, and, most recently, AI-based classifiers trained to spot synthetic content. Each layer catches different manipulation types.

    Detection layer What it catches Typical method
    Visual/manual review Obvious splicing, mismatched lighting, repeated backgrounds Trained editor or reviewer inspection
    Software-assisted forensics Cloned regions, inconsistent noise patterns, hidden splice lines Contrast/histogram enhancement in tools such as ImageJ; error-level and JPEG-artefact analysis
    AI-based screening Cross-figure and cross-manuscript duplication, rotated/mirrored reuse, synthetic image artefacts Commercial platforms such as Proofig and ImageTwin, integrated via the STM Integrity Hub

    The International Association of Scientific, Technical and Medical Publishers (STM) launched its Integrity Hub in 2022 specifically so member publishers could share signals — including image-duplication flags — across manuscripts before they reach peer review, rather than each journal screening in isolation. The Committee on Publication Ethics (COPE) publishes a companion flowchart for what an editor should do once a screening tool raises a suspected-manipulation flag, covering author correspondence, raw-data requests, and escalation to institutional investigation.

    How Is AI-Generated Fabrication Changing Image-Integrity Screening in 2026?

    Duplication-detection algorithms work by matching pixel regions against other images in a database or manuscript. That approach struggles against a newer threat: images generated wholesale by diffusion or generative-adversarial models, which contain no duplicated pixels to match because every pixel is synthetic. A fabricated Western blot or flow-cytometry plot produced this way can pass a same-image duplication check while still depicting an experiment that never happened.

    This is the gap existing FFP and paper-mill guidance largely predates. Screening vendors are responding by adding generative-artefact detectors — models trained to spot the statistical fingerprints diffusion models leave behind (unnatural noise distributions, repeating micro-textures, implausible optical consistency) rather than searching for copies. Retraction Watch has tracked a rising number of retractions citing AI-generated or “nonsensical” figures since 2023, a trend distinct from — and additive to — the classic clone-and-splice cases the 2016 Bik study catalogued. Institutions and publishers now need two separate detection pipelines: similarity-matching for reused images, and artefact/statistical analysis for wholly synthetic ones.

    What Happens During a Research Misconduct Investigation Into Images?

    Once a screening tool or reviewer flags a suspected image, most institutions follow a two-stage process: an initial inquiry to establish whether the allegation has substance, followed by a formal investigation if it does. Investigators typically request the original, unprocessed image files, any laboratory notebooks describing acquisition, and metadata showing capture date and editing history. Research administration offices coordinating these inquiries generally work to institutional timelines rather than journal timelines, since a retraction outcome depends on the institution’s finding, not the publisher’s screening flag alone.

    Outcomes range from an author-issued correction (where the error was inadvertent and does not affect conclusions) through to retraction and a formal misconduct finding recorded against the researcher, which can trigger funder debarment or employment consequences depending on jurisdiction.

    Answer-First Questions

    What is image manipulation in research?

    Image manipulation in research is the alteration of a digital scientific image — through cloning, splicing, selective erasure, or software adjustment — in a way that changes what the image communicates about the underlying data. Uniform, disclosed adjustments to brightness or contrast are acceptable; selective, undisclosed changes that alter scientific meaning are not.

    What are some examples of research misconduct?

    Research misconduct is generally defined as fabrication, falsification, or plagiarism (FFP). Examples include inventing data that was never collected, splicing unrelated gel lanes into one figure, duplicating a microscopy image to represent two different conditions, and presenting another researcher’s text or data as one’s own.

    What are the negative impacts of image manipulation?

    Manipulated images can misdirect an entire research field, waste replication effort and funding, and — in biomedical contexts — inform clinical decisions based on results that never occurred. A single high-profile retraction linked to fabricated figures can also delay legitimate follow-on research for years while the record is corrected.

    What is an example of image manipulation in a published paper?

    A commonly documented example is lane splicing: joining gel or blot lanes from different experiments and presenting the composite as a single continuous exposure without a dividing line or disclosure, so the figure implies all samples were run and imaged together when they were not.

    What Are the Implications for Institutions and Publishers?

    Publishers integrating image screening into submission workflows (via STM Integrity Hub member tools) shift detection earlier, before peer review rather than after publication, which reduces the volume of post-publication corrections research administration offices must manage. For institutions, the practical implication is that image-integrity training now needs two tracks: the long-established Rossner–Yamada rules on acceptable processing, and newer guidance on recognising signs of wholly synthetic, AI-generated figures, which look different from spliced or cloned ones and are not caught by the same tools.

    Where Image-Integrity Screening Is Heading

    Image manipulation will keep sitting inside the falsification arm of research misconduct policy, but the detection toolkit is bifurcating: similarity-matching tools such as Proofig and ImageTwin remain effective against duplication and splicing, while a newer generation of generative-artefact detectors is needed for AI-synthesised figures that contain no copied pixels at all. Institutions, journals, and funders that treat these as one problem risk missing the category their existing tools cannot see.

    Research administrators overseeing integrity policy and investigations can find further framework context in CASRAI’s research administration resources.

  • CRediT Taxonomy Investigation: Not Misconduct

    The credit taxonomy investigation role — formally “Investigation” in CRediT — covers hands-on data and evidence collection: running experiments, gathering samples, and testing hypotheses. It has no connection to a research-misconduct investigation, which is a formal institutional inquiry into fabrication, falsification, or plagiarism. The two share a word, not a meaning, and that overlap causes recurring confusion on author contribution forms.

    CRediT — the Contributor Roles Taxonomy — is a controlled vocabulary of 14 roles used to describe how each named author contributed to a research output. CASRAI originated CRediT in 2014; the standard is now stewarded by NISO as ANSI/NISO Z39.104-2022, and its 14 role definitions are maintained at credit.niso.org.

    Table of contents

    What does “Investigation” mean in the CRediT taxonomy?

    Under ANSI/NISO Z39.104-2022, the credit taxonomy investigation role is defined as “conducting a research and investigation process, specifically performing the experiments, or data/evidence collection.” It is one of 14 defined contributor roles, sitting alongside Conceptualization, Methodology, Formal Analysis, and ten others.

    The role covers the operational middle of a study: the point where a planned method is actually carried out and data starts to exist. NISO’s role definition lists the following as typical Investigation tasks:

    • Following or modifying methods to collect or generate quantitative or qualitative data
    • Testing research hypotheses and documenting the research process
    • Searching and reviewing literature, samples, data, and other evidence
    • Reporting findings for further discussion, analysis, and exchange of ideas

    None of this concerns wrongdoing. A contributor credited with Investigation did fieldwork, ran assays, coded interviews, or otherwise generated the study’s raw material — nothing more, nothing less.

    How is CRediT’s Investigation role different from a misconduct investigation?

    A research-misconduct investigation is a formal institutional process triggered by a credible allegation of fabrication, falsification, or plagiarism. In the United States, the Office of Research Integrity defines these three categories under 42 CFR Part 93, the federal policy governing PHS-funded research. In the UK, institutions follow the UK Research Integrity Office (UKRIO) procedure and the Concordat to Support Research Integrity, and publishers typically follow COPE’s investigation flowcharts once a concern is raised.

    The two processes could not be more different in stakes, actors, or timing. The table below sets out the distinction — and adds a third homonym that also trips up search results: the everyday financial “credit investigation” run by lenders.

    Aspect CRediT “Investigation” role Research-misconduct investigation Financial “credit investigation”
    What it is One of 14 standard contributor-role labels A formal inquiry into research integrity breaches A lender’s check of a borrower’s repayment history
    Governed by ANSI/NISO Z39.104-2022 (CRediT) Institutional policy, UKRIO/COPE (UK), 42 CFR Part 93/ORI (US) Consumer-credit and lending regulation
    Triggered by Submitting a manuscript with an author contribution statement A credible allegation of fabrication, falsification, or plagiarism A loan or credit application
    Who is involved Named authors/contributors and the corresponding author Research integrity officer, appointed committee, the accused Lender, credit reference agency, applicant
    Typical outcome A credited line in the published contribution statement Finding of misconduct, correction, retraction, or exoneration Loan approval, denial, or adjusted terms

    Why does the confusion keep happening on contribution forms?

    Editors and journal staff routinely field author queries asking whether ticking “Investigation” on a CRediT form invites scrutiny of their conduct. It does not. The confusion has three compounding causes.

    First, the word “investigation” already has a dominant everyday meaning tied to wrongdoing — police investigations, misconduct investigations, workplace investigations — so authors default to that association before reading the CRediT-specific definition. Second, publisher-facing CRediT forms often list all 14 roles as bare labels with no inline definition, forcing authors to look up what each term means mid-submission. Third, search behaviour reflects a genuine third homonym: “credit investigation” is also standard terminology in consumer lending, where it means a lender checking a borrower’s repayment history — a completely unrelated financial process that has nothing to do with either scholarly authorship or research integrity.

    This is a naming problem, not a substantive ambiguity. Once a contributor sees the full NISO definition — data/evidence collection — the confusion resolves immediately. The friction is entirely at the point of first encounter, typically an unlabelled checkbox in a submission system.

    How should authors and editors correctly apply the role?

    Authors should select Investigation whenever they personally performed experiments, collected data, ran surveys or interviews, or gathered samples and evidence for the study — regardless of whether they also held other roles such as Methodology or Formal Analysis. CRediT roles are not mutually exclusive; a single contributor commonly holds several.

    Editors and journal staff can reduce the confusion at source by adding the one-line NISO definition directly beside each role checkbox in submission systems, rather than relying on authors to consult an external reference. This single change removes almost all first-time-user hesitation around the Investigation label.

    Institutions drafting internal contribution-disclosure policies should keep CRediT role assignment procedurally separate from any research-integrity policy documentation, even where both appear in the same manuscript-submission workflow, so that the two processes are never conflated administratively.

    Frequently asked questions

    What does “Investigation” mean in CRediT taxonomy?

    In CRediT, “Investigation” is the role covering the research and investigation process itself — performing experiments or collecting data and evidence. It sits alongside 13 other defined roles under ANSI/NISO Z39.104-2022 and describes hands-on data generation, not any form of wrongdoing inquiry.

    What is the CRediT taxonomy?

    CRediT (Contributor Roles Taxonomy) is a standardised, 14-role controlled vocabulary for describing each named author’s specific contribution to a scholarly work. CASRAI originated it in 2014; NISO now stewards it as ANSI/NISO Z39.104-2022, and major publishers including Elsevier, Wiley, Sage, and Taylor & Francis request it at submission.

    What are the criteria for authorship?

    ICMJE’s Recommendations set out four authorship criteria — substantial contribution to conception/design or data acquisition/analysis; drafting or critical revision; final approval of the published version; and accountability for the work’s integrity. Some secondary sources miscount this as five by splitting the first criterion.

    Does “credit investigation” mean the same as CRediT’s Investigation role?

    No. A financial credit investigation is a lender’s check of a borrower’s repayment history before approving a loan — a consumer-lending process with no connection to scholarly authorship. It shares only the surface phrase with CRediT’s data/evidence-collection role.

    Implications for editors and institutions

    Naming collisions like this one are a small but measurable source of submission friction: every unlabelled checkbox that requires an author to context-switch away from the manuscript to look up a definition adds time and risk of miscoding to the metadata that journals, funders, and indexers eventually rely on. Contribution statements feed downstream systems — CrossRef metadata, ORCID records, institutional research-information systems — so a mislabelled or abandoned Investigation entry is not a cosmetic error; it degrades the accuracy of the scholarly record’s provenance data.

    As more funders and institutions move toward requiring structured contribution statements alongside authorship, the practical fix sits with journal and submission-system design, not with the taxonomy itself: inline definitions, tooltips, or a linked glossary at the point of role selection resolve the ambiguity before it becomes a support ticket. The taxonomy’s 14 roles remain stable under ANSI/NISO Z39.104-2022; what needs to improve is how clearly each one is presented at first encounter.